Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Non-randomized, Phase IB Study to Characterize Safety, Tolerability and Recommended Dose of Tinostamustine and Nivolumab in Patients With Refractory, Locally Advanced or Metastatic MelAnoma

NCT03903458 is registered in ClinicalTrials.gov with Markus Joerger as lead sponsor.

NCT NCT03903458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03903458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Non-randomized, Phase IB Study to Characterize Safety, Tolerability and Recommended Dose of Tinostamustine and Nivolumab in Patients With Refractory, Locally Advanced or Metastatic MelAnoma
Lead sponsor
Markus Joerger
Phase
Phase 1
Overall status
Unknown status
Start date
March 7, 2019
Completion date
March 15, 2024
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma